drugset / Trial / NCT02455297
Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of this study is to assess objective response rate (ORR) in patients with relapsed or refractory MCL who failed ibrutinib treatment or were unable to tolerate ibrutinib.
Timeline
- Start
- 2015-08-24
- Primary completion
- 2016-04-08
- Completion
- 2016-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | 45 mg | Intravenous |
| Subject | Copanlisib | Small molecule | 60 mg | Intravenous |